Anidulafungin
Indication :
Dosing :
Safety and efficacy not established in children. 3 mg/m² IV as loading dose followed by 1.5 mg/m²/dose IV once a day for 14 days after last culture report is positive.
Adverse Effect :
Diarrhea, hypokalemia, elevated transaminases, urticaria, flushing, hypotension.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Not dialysed. Dose as in normal renal function |
| HD | Not dialysed. Dose as in normal renal function |
| HDF/High flux | Unlikely to be dialysed. Dose as in normal renal function |
| CAV/VVHD | Unlikely to be dialysed. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended. Consider risk: benefit ratio of continuing treatment if liver functions deteriorate during anidulafungin treatment.